Acceleron Pharma (XLRN) Stock Balance Sheet
NASDAQ:XLRN - Nasdaq -
| MRQ (2021-9-30) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | 2017 (2017-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 336.46M | 671.00M | 237.70M | 144.10M | 100.20M | |||
| Marketable Securities | 254.11M | 179.00M | 193.70M | 147.30M | 177.10M | |||
| Receivables | 34.20M | 26.10M | 8.50M | 7.00M | 3.60M | |||
| Other Current Assets | 71.84M | 17.30M | 10.00M | 7.70M | 4.40M | |||
| Total Current Assets | 696.61M | 893.30M | 449.90M | 306.00M | 285.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 27.75M | 29.80M | 30.70M | 7.10M | 7.00M | |||
| Investments And Advances | 61.95M | 7.60M | 22.50M | 0.00 | 95.70M | |||
| Other Non-Current Assets | 1.54M | 1.70M | 1.80M | 1.70M | 1.20M | |||
| Total Non-Current Assets | 91.24M | 39.00M | 55.00M | 8.80M | 104.00M | |||
| TOTAL ASSETS | 787.85M | 932.30M | 504.90M | 314.80M | 389.20M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 52.28M | 49.20M | 30.10M | 17.60M | 13.80M | |||
| Accounts Payable | 5.09M | 8.50M | 2.30M | 400.00K | 1.10M | |||
| Other Current Liabilities | N/A | 2.50M | 1.00M | 900.00K | 1.90M | |||
| Total Current Liabilities | 57.37M | 60.20M | 33.40M | 18.90M | 16.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 12.32M | 17.10M | 22.10M | 3.90M | 7.20M | |||
| Total Non-Current Liabilities | 12.32M | 17.00M | 22.00M | 3.90M | 7.30M | |||
| TOTAL LIABILITIES | 69.69M | 77.20M | 55.40M | 22.80M | 24.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.07B | -877.40M | -711.40M | -586.50M | -473.00M | |||
| Additional Paid In Capital | 1.79B | 1.73B | 1.16B | 879.10M | 839.10M | |||
| Common Shares | 61.00K | 100.00K | 100.00K | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -398.00K | -300.00K | N/A | -600.00K | -900.00K | |||
| Shares Outstanding | 61.13M | 60.40M | 53.10M | 46.30M | 45.30M | |||
| Tangible Book Value per Share | 11.75 | 14.16 | 8.47 | 6.31 | 8.06 | |||
| Total Shareholders' Equity | 718.15M | 855.10M | 449.50M | 292.00M | 365.20M | |||
| TOTAL LIABILITIES AND EQUITY | 787.85M | 932.30M | 504.90M | 314.80M | 389.20M | |||
| Statistics | ||||||||
| Current Ratio | 12.14 | 14.84 | 13.47 | 16.19 | 17.08 | |||
| Return On Assets (ROA) | -32.35% | -17.81% | -24.73% | -37.76% | -27.86% | |||
| Return On Equity (ROE) | -35.49% | -19.42% | -27.78% | -40.71% | -29.70% | |||
All data in USD , ROIC based on taxRate of 0.21